REPLIGEN CORP acquired Spectrum, Inc. (Spectrum LifeSciences) for ~$359 million ($120M cash + ~$239M in Repligen stock), a transaction completed in August 2017, structured as combination (cash plus stock).
Spectrum, Inc. (Spectrum LifeSciences) operates in Filtration, is based in Rancho Dominguez, California, USA, had revenue of about $40.2 million (2016). Acquisition of Spectrum, Inc., a maker of hollow-fiber (HF) filtration products and KrosFlo TFF systems plus the Spectra/Por dialysis line, in a transaction Repligen called pivotal. Spectrum recorded revenue of $40.2 million in 2016. The deal substantially expanded Repligen's filtration franchise and global commercial footprint.
Hunt called it 'a pivotal transaction for Repligen that meets all of our acquisition criteria and is a major step forward in building Repligen as a global leader in bioprocessing.'
Market-leading hollow-fiber filtration with strong revenue and customer base. Combined filtration portfolio (HF + flat-sheet TFF) and expanded commercial infrastructure. Repligen Filtration franchise
This is a pivotal transaction for Repligen that meets all of our acquisition criteria and is a major step forward in building Repligen as a global leader in bioprocessing.Tony J. Hunt, President and CEO, Repligen
Spectrum has developed world-class products delivered with first-class customer service. Repligen has a proven track record of unlocking additional value and accelerating growth.Roy Eddleman, Chairman and CEO, Spectrum
Advisory firms were not disclosed for this transaction.